TDRL-551
TDRL-551 is a potent replication protein A (RPA) inhibitor (IC50 = 18 µM) . TDRL-551 inhibits RPA-DNA interaction and increases the anti-cancer efficacy of Platinum (Pt) -based chemotherapy. TDRL-551 can be used for the research of cancer, such as non-small cell lung cancer (NSCLC) [1].
Product Specifications
CAS Number
1644626-43-6
UNSPSC
12352005
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tdrl-551.html
Purity
99.84
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(CCCC(N1N=C(CC1C2=CC3=CC=C(C=C3N=C2Cl)OCC)C4=CC=C(C=C4)I)=O)O
Molecular Formula
C25H23ClIN3O4
Molecular Weight
591.83
References & Citations
[1]Mishra AK, et al. Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. Biochem Pharmacol. 2015 Jan 1;93 (1) :25-33.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
